FDA Cuts IMDELLTRA Monitoring Time, Easing Access for Amgen's Lung Cancer Drug
AMGN sits 40% above its 52-week low of $269.77.
Summary
The FDA approved a label update for Amgen's IMDELLTRA, reducing required monitoring after the first two infusions from 22-24 hours to 6-8 hours. This lowers the administrative burden and could expand use in community clinics, where 80-85% of U.S. patients are treated. The change directly addresses a key friction point for the drug's uptake in extensive-stage small cell lung cancer. Next-day assessments remain, preserving safety oversight. This follows a period of mixed news for Amgen, including a strong Q2 beat and a recent share drop on competitor data, making this a positive incremental development.
At the time of this announcement, AMGN was trading at $378.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $204B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.